PE firms linked to sale of Glaxo non-core brands
A number of private equity groups are thought to be interested in acquiring a product portfolio being sold by GlaxoSmithKline (GSK).
Advent International, Warburg Pincus and Cinven are all thought to be in talks over acquiring the non-core assets in a deal that could we worth around £500m.
It is not yet clear whether any of the firms are working joint bids or plan to buy the assets independently.
The brands amount to about 10% of GSK's consumer healthcare portfolio.
More on UK / Ireland
Inflexion to exit Xtrac in SBO to MiddleGround Capital
Sale of UK-based transmission-systems manufacturer marks Buyout Fund IVтs seventh exit
Federated Hermes raises USD 486m for fifth co-investment fund
Fund surpassed its USD 400m target; its 2018-vintage predecessor raised USD 600m against a USD 350m target
FPE Capital acquires, merges NoBlue and Elevate2
GPтs investment in NetSuite partners marks fifth investment out of third fund
Palatine reaps 6x money on SBO of Anthesis to Carlyle
GP will be reinvesting in UK-headquartered sustainability firm, acquiring a minority stake
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds